CH674939A5 - - Google Patents

Download PDF

Info

Publication number: CH674939A5
Authority: CH; Switzerland
Prior art keywords: gly; val; ala; lys; asp
Prior art date: 1986-06-02

Application number

CH2040/87A

Other languages

English (en)

French (fr)

Inventor

Romano Deghenghi

Original Assignee

Debiopharm Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-02

Filing date

1987-05-25

Publication date

1990-08-15

1987-05-25 Application filed by Debiopharm Sa filed Critical Debiopharm Sa

1990-08-15 Publication of CH674939A5 publication Critical patent/CH674939A5/fr

Links

102000010750 Metalloproteins Human genes 0.000 claims description 20
108010063312 Metalloproteins Proteins 0.000 claims description 20
238000000034 method Methods 0.000 claims description 18
239000002184 metal Substances 0.000 claims description 15
229910052751 metal Inorganic materials 0.000 claims description 15
150000002739 metals Chemical class 0.000 claims description 12
102000006410 Apoproteins Human genes 0.000 claims description 11
108010083590 Apoproteins Proteins 0.000 claims description 11
102000008100 Human Serum Albumin Human genes 0.000 claims description 10
108091006905 Human Serum Albumin Proteins 0.000 claims description 10
230000004071 biological effect Effects 0.000 claims description 9
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 7
239000003431 cross linking reagent Substances 0.000 claims description 7
230000008569 process Effects 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
102000004169 proteins and genes Human genes 0.000 claims description 7
108090000623 proteins and genes Proteins 0.000 claims description 7
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
150000001718 carbodiimides Chemical class 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
FMJUDUJLTNVWCH-UHFFFAOYSA-N 2-ethoxy-3-(4-hydroxyphenyl)propanoic acid Chemical compound CCOC(C(O)=O)CC1=CC=C(O)C=C1 FMJUDUJLTNVWCH-UHFFFAOYSA-N 0.000 claims description 2
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
150000001413 amino acids Chemical group 0.000 claims 2
150000002463 imidates Chemical class 0.000 claims 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
102000009027 Albumins Human genes 0.000 description 5
108010088751 Albumins Proteins 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
229910052725 zinc Inorganic materials 0.000 description 5
239000011701 zinc Substances 0.000 description 5
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
229910052802 copper Inorganic materials 0.000 description 4
239000010949 copper Substances 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
239000000539 dimer Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
150000002978 peroxides Chemical class 0.000 description 4
150000004696 coordination complex Chemical class 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229910017518 Cu Zn Inorganic materials 0.000 description 2
229910017752 Cu-Zn Inorganic materials 0.000 description 2
-1 Cu-Zn peroxide Chemical class 0.000 description 2
229910017943 Cu—Zn Inorganic materials 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000003505 Myosin Human genes 0.000 description 2
108060008487 Myosin Proteins 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000013527 degreasing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Analytical Chemistry (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CH2040/87A 1986-06-02 1987-05-25 CH674939A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB8613315A GB2191200B (en)	1986-06-02	1986-06-02	Process for preparing conjugates of metalloproteins and novel derivatives thereof

Publications (1)

Publication Number	Publication Date
CH674939A5 true CH674939A5 (de)	1990-08-15

Family

ID=10598769

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH2040/87A CH674939A5 (de)	1986-06-02	1987-05-25

Country Status (10)

Country	Link
JP (1)	JPS62292800A (de)
BE (1)	BE1002130A3 (de)
CH (1)	CH674939A5 (de)
DE (1)	DE3718476A1 (de)
DK (1)	DK280187A (de)
ES (1)	ES2004734A6 (de)
FR (1)	FR2603287B1 (de)
GB (1)	GB2191200B (de)
IT (1)	IT1207805B (de)
NL (1)	NL8701254A (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1317895B1 (it) *	2000-08-10	2003-07-15	Univ Napoli Federico Ii	Pseudo-metalloproteine, loro preparazione e loro uso.
MX354530B (es) *	2013-02-27	2018-02-19	Univ Autonoma Del Estado De Morelos	Composiciones que comprenden immp para coadyuvar al desarrollo, crecimiento y mejora de los parámetros productivos de animales de interés zootécnico, y uso de las mismas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1168150A (en) *	1981-12-18	1984-05-29	The Governors Of The University Of Alberta	Targeting conjugates of albumin and therapeutic agents

1986
- 1986-06-02 GB GB8613315A patent/GB2191200B/en not_active Expired - Fee Related
1987
- 1987-05-25 CH CH2040/87A patent/CH674939A5/fr not_active IP Right Cessation
- 1987-05-26 NL NL8701254A patent/NL8701254A/nl not_active Application Discontinuation
- 1987-05-29 ES ES8701587A patent/ES2004734A6/es not_active Expired
- 1987-05-29 JP JP62137600A patent/JPS62292800A/ja active Pending
- 1987-06-01 IT IT8705187A patent/IT1207805B/it active
- 1987-06-01 FR FR878707639A patent/FR2603287B1/fr not_active Expired - Fee Related
- 1987-06-01 DK DK280187A patent/DK280187A/da not_active Application Discontinuation
- 1987-06-01 BE BE8700605A patent/BE1002130A3/fr not_active IP Right Cessation
- 1987-06-02 DE DE19873718476 patent/DE3718476A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
GB2191200A (en)	1987-12-09
DK280187D0 (da)	1987-06-01
IT1207805B (it)	1989-06-01
BE1002130A3 (fr)	1990-07-24
IT8705187A0 (it)	1987-06-01
DE3718476A1 (de)	1987-12-03
NL8701254A (nl)	1988-01-04
DK280187A (da)	1987-12-03
JPS62292800A (ja)	1987-12-19
FR2603287A1 (fr)	1988-03-04
FR2603287B1 (fr)	1991-02-08
GB8613315D0 (en)	1986-07-09
GB2191200B (en)	1990-07-11
ES2004734A6 (es)	1989-02-01

Legal Events

Date	Code	Title	Description
1993-01-29	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
EP0259197B1 (de)	1991-09-25	Makromolekulare Hämoglobinkonjugate, Verfahren zu ihrer Herstellung und ihre Verwendungen
JP2707241B2 (ja)	1998-01-28	代用血漿剤
EP0338916B1 (de)	1992-07-01	Makromolekulare Hämoglobinkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendungen
Kini et al.	1989	Role of cationic residues in cytolytic activity: modification of lysine residues in the cardiotoxin from Naja nigricollis venom and correlation between cytolytic and antiplatelet activity
Husain et al.	1983	Electron transfer flavoprotein from pig liver mitochondria. A simple purification and re-evaluation of some of the molecular properties
AU2003299700B2 (en)	2009-03-26	Modified hemoglobin and methods of making same
EP0080401B1 (de)	1992-07-29	Krebshemmende Heilmittel für die Behandlung von T-Leukämien, bestehend aus der A-Kette des Rizinus und einem spezifischen monoklonalen Antikörper
Lappi et al.	1985	Characterization of a Saponaria officinalis seed ribosome-inactivating protein: immunoreactivity and sequence homologies
JPH03501208A (ja)	1991-03-22	細胞毒性結合体
US7144989B2 (en)	2006-12-05	Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
EP1284994B1 (de)	2004-07-28	Verwendung eines extrazellulären hämoglobins mit höherem molekulargewicht als blutersatz
CA1338415C (en)	1996-06-25	C-terminal amidating enzyme composition, process for preparing, and use of the same
AU2018247928A1 (en)	2019-10-31	C4BP-based compounds for treating immunological diseases
CH674939A5 (de)	1990-08-15
JPH09500639A (ja)	1997-01-21	ニッケルを含まないヘモグロビンおよびこのようなヘモグロビンを生産するための方法
US8021858B2 (en)	2011-09-20	Method for making polyalkylene oxide modified hemoglobin
Vanbueren et al.	1993	An immunization method for generation of high affinity antisera against glucose transporters useful in immunohistochemistry
Bonneaux et al.	1995	Fixation of various aldehydic dextrans onto human hemoglobin: study of conjugate stability
Nezlin et al.	1993	Proteins separated from human IgG molecules
EP0528716A1 (de)	1993-02-24	Derivate von humanem Hämoglobin, Verfahren zu deren Herstellung, davon abgeleitete Produkte und Verwendung dieser Derivate und Produkte
WO2024023068A1 (en)	2024-02-01	Use of an annelid molecule for treating and/or preventing at least one complement-activation associated disease
JPH0222297A (ja)	1990-01-25	新規な糖蛋白質
Odajima et al.	1998	A chemical modification of myeloperoxidase and lactoperoxidase with 2‐(O‐methoxypolyethylene glycol)‐4, 6‐dichloro‐s‐triazine (activated PEG1)
AU3463999A (en)	1999-10-18	Immune response modulator alpha-2 macroglobulin complex
Wistow et al.	1983	Schiff's base formation in the lens protein γ-crystallin